These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29642889)

  • 21. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.
    Mauguen A; Pignon JP; Burdett S; Domerg C; Fisher D; Paulus R; Mandrekar SJ; Belani CP; Shepherd FA; Eisen T; Pang H; Collette L; Sause WT; Dahlberg SE; Crawford J; O'Brien M; Schild SE; Parmar M; Tierney JF; Le Pechoux C; Michiels S;
    Lancet Oncol; 2013 Jun; 14(7):619-26. PubMed ID: 23680111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
    Kehl KL; Riely GJ; Lepisto EM; Lavery JA; Warner JL; LeNoue-Newton ML; Sweeney SM; Rudolph JE; Brown S; Yu C; Bedard PL; Schrag D; Panageas KS;
    JAMA Netw Open; 2021 Jul; 4(7):e2117547. PubMed ID: 34309669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
    Wei Z; Yang X; Ye X; Feng Q; Xu Y; Zhang L; Sun W; Dong Y; Meng Q; Li T; Wang C; Li G; Zhang K; Li P; Bi J; Xue G; Sun Y; Sheng L; Liu B; Yu G; Ren H; Wang J; Sun L; Chen S; Geng D; Zhang B; Xu X; Zhang L; Sun D; Xu X; Diao C; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zheng A; Fan W; Li Y; Li F; Fan H; Zou Z; Li Q; Tian H
    Eur Radiol; 2020 May; 30(5):2692-2702. PubMed ID: 32020400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Value of surgery for stage IIIa non-small cell lung cancer].
    Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.
    Taugner J; Eze C; Käsmann L; Roengvoraphoj O; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
    Radiat Oncol; 2020 Jun; 15(1):148. PubMed ID: 32517716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Automated estimation of disease recurrence in head and neck cancer using routine healthcare data.
    Ricketts K; Williams M; Liu ZW; Gibson A
    Comput Methods Programs Biomed; 2014 Dec; 117(3):412-24. PubMed ID: 25306243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
    Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
    JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
    Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation.
    Barquín M; Calvo V; García-García F; Nuñez B; Sánchez-Herrero E; Serna-Blasco R; Auglytė M; Carcereny E; Rodriguez-Abreu D; López Castro R; Guirado M; Camps C; Bosch-Barrera J; Massuti B; Ortega AL; Del Barco E; Gonzalez-Larriba JL; Aguiar D; García-Campelo R; Dómine M; Agraso S; Sala MA; Oramas J; Bernabé R; Blanco R; Parejo C; Cruz A; Menasalvas E; Royuela A; Romero A; Provencio M
    Cancer Epidemiol; 2020 Aug; 67():101737. PubMed ID: 32450544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer : A retrospective study of elderly patients with stage III disease.
    Franceschini D; De Rose F; Cozzi L; Navarria P; Clerici E; Franzese C; Comito T; Tozzi A; Iftode C; D'Agostino G; Sorsetti M
    Strahlenther Onkol; 2017 May; 193(5):385-391. PubMed ID: 28168322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
    Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
    Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.
    He L; Teng Y; Jin B; Zhao M; Yu P; Hu X; Zhang J; Li S; Gao Y; Liu Y
    BMC Cancer; 2010 Dec; 10():681. PubMed ID: 21156055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
    Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
    Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
    Wang Y; Li Y; Xia L; Niu K; Chen X; Lu D; Kong R; Chen Z; Sun J
    Clin Transl Oncol; 2018 Mar; 20(3):366-373. PubMed ID: 28776311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.